Literature DB >> 28663009

The potent cell permeable calpain inhibitor MDL28170 affects the interaction of Leishmania amazonensis with macrophages and shows anti-amastigote activity.

Fernanda A Marinho1, Leandro S Sangenito1, Simone S C Oliveira1, Luciana B De Arruda2, Claudia M D'Ávila-Levy3, André L S Santos4, Marta H Branquinha5.   

Abstract

Since the discovery of the28 first drugs used in leishmaniasis treatment up to now, the search for compounds with anti-Leishmania activity without toxic effects and able to overcome the emergency of resistant strains remains a major goal to combat this neglected disease. With this in mind, in the present work, we evaluated the effects of the calpain inhibitor MDL28170 on the interaction process of Leishmania amazonensis promastigote forms with murine peritoneal macrophages and on the intracellular amastigotes. Our results showed that the calpain inhibitor MDL28170 at 15 and 30μM significantly reduced the interaction process of promastigotes with macrophages by 16% and 41%, respectively. The inhibitor was also able to drastically reduce the number of infected macrophages in a time- and dose-dependent manner: after only 24h, MDL28170 was able to significantly diminish the infection rate, presenting an IC50 value of 18.2μM for amastigotes. The treatment with MDL28170 did not alter the nitric oxide production, but the production of TNF-α was significantly raised. Altogether, the results presented here contribute to the search of new proteolytic inhibitors able to act in a selective and effective manner against the diseases caused by trypanosomatids.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Calpain inhibitor; Interaction process; Intracellular amastigotes; Leishmania amazonensis; Leishmaniasis

Mesh:

Substances:

Year:  2017        PMID: 28663009     DOI: 10.1016/j.parint.2017.06.010

Source DB:  PubMed          Journal:  Parasitol Int        ISSN: 1383-5769            Impact factor:   2.230


  6 in total

1.  Susceptibility of promastigotes and intracellular amastigotes from distinct Leishmania species to the calpain inhibitor MDL28170.

Authors:  Pedro Soares de Sousa Araújo; Simone Santiago Carvalho de Oliveira; Claudia Masini d'Avila-Levy; André Luis Souza Dos Santos; Marta Helena Branquinha
Journal:  Parasitol Res       Date:  2018-05-04       Impact factor: 2.289

2.  Proteolytic inhibitors as alternative medicines to treat trypanosomatid-caused diseases: experience with calpain inhibitors.

Authors:  Vítor Ennes-Vidal; André Luis Souza Dos Santos; Marta Helena Branquinha; Claudia Masini d'Avila-Levy
Journal:  Mem Inst Oswaldo Cruz       Date:  2022-03-25       Impact factor: 2.743

3.  Comparative analysis between four model nanoformulations of amphotericin B-chitosan, amphotericin B-dendrimer, betulinic acid-chitosan and betulinic acid-dendrimer for treatment of Leishmania major: real-time PCR assay plus.

Authors:  Ali Khamesipour; Amitis Ramezani; Tahereh Zadeh Mehrizi; Mehdi Shafiee Ardestani; Hasan Ebrahimi Shahmabadi; Mostafa Haji Molla Hoseini; Nariman Mosaffa
Journal:  Int J Nanomedicine       Date:  2019-09-24

Review 4.  The Diverse Calpain Family in Trypanosomatidae: Functional Proteins Devoid of Proteolytic Activity?

Authors:  Vítor Ennes-Vidal; Marta Helena Branquinha; André Luis Souza Dos Santos; Claudia Masini d'Avila-Levy
Journal:  Cells       Date:  2021-02-01       Impact factor: 6.600

5.  Antileishmanial Efficacy of the Calpain Inhibitor MDL28170 in Combination with Amphotericin B.

Authors:  Marta H Branquinha; Pedro S S Araújo; Simone S C Oliveira; Leandro S Sangenito; Diego S Gonçalves; Sérgio H Seabra; Claudia M d'Avila-Levy; André L S Santos
Journal:  Trop Med Infect Dis       Date:  2022-02-16

6.  Novel Nanosized Chitosan-Betulinic Acid Against Resistant Leishmania Major and First Clinical Observation of such parasite in Kidney.

Authors:  Tahereh Zadeh Mehrizi; Mehdi Shafiee Ardestani; Mostafa Haji Molla Hoseini; Ali Khamesipour; Nariman Mosaffa; Amitis Ramezani
Journal:  Sci Rep       Date:  2018-08-06       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.